Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585462 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
A Phase 1 study of Cardiometabolic Disease, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 5
- Study locations
NCT06585462: Recruiting Phase 1 study of Cardiometabolic Disease, sponsored by Amgen.
NCT06585462 is a Phase 1 study of Cardiometabolic Disease that is actively recruiting participants, run by Amgen. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06585462, a Phase 1 study of Cardiometabolic Disease, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMG 513
Study Locations (5)
California
- Anaheim Clinical Trials - Anaheim
- Carilion Medical Center - Lake Forest
- Fomat Medical Research - Oxnard
Florida
- Translational Clinical Research LLC - Aventura
- Clinical Pharmacology of Miami, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 1 |
What NCT06585462 shows while recruiting
NCT06585462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 1 condition, with Cardiometabolic Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06585462 lists 5 locations in 2 states (California, Florida).
Frequently Asked Questions
What is clinical trial NCT06585462 about?
NCT06585462 is a clinical study titled "Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity". The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
What is the current status of trial NCT06585462?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-09-09. Estimated completion is 2026-10-01.
What conditions does trial NCT06585462 study?
This clinical trial studies the following conditions: Cardiometabolic Disease.
What interventions are being tested in trial NCT06585462?
The interventions under investigation include: Placebo (DRUG), AMG 513 (DRUG).
Who is sponsoring clinical trial NCT06585462?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585462 being conducted?
This trial has 5 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiometabolic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06585462's enrollment target sits among peer trials
80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI